Trial Profile
A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated With an Anthracycline and Ifosfamide
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Trabectedin (Primary) ; Dacarbazine
- Indications Leiomyosarcoma; Liposarcoma; Soft tissue sarcoma
- Focus Registrational; Therapeutic Use
- Acronyms SAR3007
- Sponsors Janssen Research & Development
- 22 Apr 2021 According to Specialised Therapeutics Asia media release, the Therapeutic Goods Administration has approved the use of YONDELIS (trabectedin), marketed by Specialised Therapeutics, for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen, based on results from this study.
- 10 Sep 2019 Results assessing the safety and efficacy of Trabectedin when administered in the inpatient versus outpatient setting (n=378), published in the Cancer
- 07 Jun 2019 Subgroup analysis results were published in the Cancer.